This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Foslevodopa
- DrugBank Accession Number
- DB16683
- Background
Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced Parkinson's Disease).
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Foslevodopa (DB16683)
- Weight
- Average: 277.169
Monoisotopic: 277.035138728 - Chemical Formula
- C9H12NO7P
- Synonyms
- 3-hydroxy-O-phosphono-L-tyrosine
- Foslevodopa
- Levodopa-4'-monophosphate
- External IDs
- ABBV-951
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmisulpride The therapeutic efficacy of Foslevodopa can be decreased when used in combination with Amisulpride. Aripiprazole The therapeutic efficacy of Foslevodopa can be decreased when used in combination with Aripiprazole. Aripiprazole lauroxil The therapeutic efficacy of Foslevodopa can be decreased when used in combination with Aripiprazole lauroxil. Asenapine The therapeutic efficacy of Foslevodopa can be decreased when used in combination with Asenapine. Brexpiprazole The therapeutic efficacy of Foslevodopa can be decreased when used in combination with Brexpiprazole. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Produodopa (AbbVie)
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Produodopa 240 mg/ml + 12 mg/ml Infusionslösung Foslevodopa (240 mg/mL) + Foscarbidopa (12 mg/mL) Injection Parenteral 2023-03-03 Not applicable Germany 
Vyalev Foslevodopa (240 mg / mL) + Foscarbidopa (12 mg / mL) Solution Subcutaneous Abbvie 2024-02-05 Not applicable Canada 
Categories
- ATC Codes
- N04BA07 — Foslevodopa and decarboxylase inhibitor
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 37NQZ0J76I
- CAS number
- 97321-87-4
- InChI Key
- YNDMEEULGSTYJT-LURJTMIESA-N
- InChI
- InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1
- IUPAC Name
- (2S)-2-amino-3-[3-hydroxy-4-(phosphonooxy)phenyl]propanoic acid
- SMILES
- N[C@@H](CC1=CC=C(OP(O)(O)=O)C(O)=C1)C(O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 113330
- ChEBI
- 192509
- ChEMBL
- CHEMBL4594379
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Active Not Recruiting Treatment Parkinson's Disease (PD) 2 somestatus stop reason just information to hide 3 Completed Treatment Parkinson's Disease (PD) 2 somestatus stop reason just information to hide 1 Completed Treatment Parkinson's Disease (PD) 3 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Parenteral Solution Subcutaneous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.66 mg/mL ALOGPS logP -0.74 ALOGPS logP -1.3 Chemaxon logS -2.2 ALOGPS pKa (Strongest Acidic) 1.26 Chemaxon pKa (Strongest Basic) 9.41 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 150.31 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 59.95 m3·mol-1 Chemaxon Polarizability 23.74 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00lr-0090000000-88917fd13fc22aa1cafa Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9020000000-b4611a6c2143f2082520 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00lr-0970000000-5bc3ba4e5cbcb8592b31 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9000000000-5e937135c9d10816e54b Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9000000000-455d394fad6c23f2fb80 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-053r-0900000000-524409450a9ad520ac0d Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at April 01, 2021 21:58 / Updated at May 01, 2024 10:58